Pfizer Inc. is one of the most recognized names in global pharmaceuticals. Founded in 1849, the company has shaped modern medicine through breakthroughs in antibiotics, vaccines, oncology, cardiovascular treatments, and most recently, COVID-19 therapies. With its global footprint, strong research pipeline, and history of steady dividend payments, Pfizer (NYSE: PFE) is closely followed by both institutional and retail investors.
- What is Pfizer’s Current Share Price?
- Latest Earnings and Revenue Performance
- Pfizer’s 2025 Profit Forecast Revision
- Outlook for the Updated COVID-19 Vaccine
- Why Pfizer Halted the Obesity Drug Development
- Implications of Selling Its Haleon Stake
- Competitive Landscape: Pfizer vs Rivals
- When is Pfizer’s Next Earnings Report?
- Dividend Yield and Payout History
- Analyst Sentiment: Buy, Sell, or Hold?
- Conclusion
For those who track healthcare equities, Fintechzoom PFE stock coverage has become a common resource. Traders look at Pfizer not only as a healthcare leader but also as a benchmark of how large-cap pharmaceutical companies adapt in an evolving healthcare landscape. With shifting demand for vaccines, changing regulatory frameworks, and rising competition in obesity and oncology, Pfizer’s financial performance is constantly in the spotlight. Investors also consider whether it belongs among the Fintechzoom best stocks to buy now, given its valuation and dividend strength.
This blog reviews Pfizer’s latest stock updates, key developments, and investor questions shaping its outlook.
What is Pfizer’s Current Share Price?
As of September 10, 2025, Pfizer’s stock trades around $24.71 per share. The stock has been under pressure in recent years due to declining COVID-19 vaccine sales and investor skepticism about pipeline growth. However, price levels in the mid-$20s are historically low for Pfizer, making many long-term investors reconsider its value proposition.
The daily price of Fintechzoom PFE stock is followed closely because small fluctuations can reflect broader healthcare sector sentiment. Unlike fast-moving tech stocks, pharmaceutical equities tend to move with regulatory announcements, clinical trial data, and quarterly earnings reports. For income-focused investors, price stability is less important than the consistent dividend, which Pfizer has maintained through market cycles.
Latest Earnings and Revenue Performance
Pfizer’s most recent quarterly results show resilience despite industry headwinds. For Q2 2025, the company reported $14.65 billion in revenue, exceeding Wall Street’s estimates. Earnings per share (EPS) came in at $0.78, also ahead of the expected $0.58.
The growth came from a combination of cost controls, favorable foreign exchange rates, and better-than-expected product sales across oncology and rare disease treatments. Although COVID-19 vaccine revenue is declining from pandemic highs, Pfizer’s diversified portfolio continues to generate steady income.
Investors tracking Pfizer’s performance often highlight how earnings stability, even in transition years, keeps the company attractive for long-term portfolios. Unlike speculative biotech names, Pfizer’s scale and multiple revenue streams reduce the risk of earnings collapse, making it a steady option among top healthcare stocks.
Pfizer’s 2025 Profit Forecast Revision
A major confidence booster came when Pfizer raised its 2025 profit forecast. Originally guiding earnings in the range of $2.80–$3.00 per share, the company now expects $2.90–$3.10. This increase stems primarily from aggressive cost-cutting programs and operational efficiencies.
Management also pointed to foreign exchange gains and stable demand in oncology as drivers. Cost savings from restructuring initiatives are expected to contribute several hundred million dollars in margin improvements over the next two years.
For analysts covering Fintechzoom PFE stock, the raised guidance signals that Pfizer is focused on profitability even in the face of pipeline challenges. Many retail traders now weigh whether Pfizer deserves a place among the Fintechzoom best stocks to buy now given its attractive valuation compared to peers.
Outlook for the Updated COVID-19 Vaccine
Pfizer’s partnership with BioNTech continues to be central to its vaccine strategy. In September 2025, the companies announced that their updated COVID-19 vaccine produced a stronger immune response—at least a fourfold increase in neutralizing antibodies—particularly in older adults and individuals with chronic conditions.
This is critical because health experts still expect seasonal demand for COVID-19 boosters, similar to influenza vaccines. While overall sales may not reach pandemic levels, a steady recurring revenue stream could emerge.
Pipeline Highlights
Beyond vaccines, Pfizer’s current research and development pipeline covers multiple areas of innovation:
- Oncology: Expanding treatments for breast and prostate cancers
- Vaccines: Updated COVID-19 booster and influenza partnerships
- Rare Diseases: Gene therapy programs progressing through clinical phases
- Immunology: Biologics for autoimmune conditions
Investors following Fintechzoom PFE stock note that vaccine success, even at lower demand levels, provides Pfizer with cash flows to reinvest in new therapies. For long-term portfolios seeking healthcare exposure, the presence of a recurring vaccine market strengthens the case for Pfizer being on the list of Fintechzoom best stocks to buy now.
Why Pfizer Halted the Obesity Drug Development
One of the biggest setbacks for Pfizer in 2025 was the discontinuation of its obesity pill danuglipron. Although the drug showed promise as an oral alternative to injectable treatments like Novo Nordisk’s Wegovy, the program was halted after a trial participant experienced potential drug-induced liver injury.
This was disappointing for investors, as the obesity drug market is projected to reach over $100 billion in annual sales within a decade. Pfizer’s exit reduces its near-term potential in one of the hottest therapeutic areas.
Still, analysts covering Fintechzoom PFE stock argue that Pfizer’s pipeline is broad enough to absorb this loss. Oncology and rare disease therapies remain major growth drivers. But it also raises questions for traders about whether Pfizer remains competitive enough to be considered one of the Fintechzoom best stocks to buy now compared to faster-moving biotech peers.
Implications of Selling Its Haleon Stake
Earlier in 2025, Pfizer completed its divestiture of consumer health company Haleon, selling its entire stake for approximately $3.24 billion. This move marks Pfizer’s full exit from the consumer healthcare business, following its earlier spin-off.
The sale strengthens Pfizer’s balance sheet and frees management to focus exclusively on core pharmaceuticals and vaccines. While Haleon’s consumer products offered stable cash flows, they did not fit Pfizer’s strategy of pursuing high-margin, innovation-driven treatments.
This divestment is viewed positively, as it reflects Pfizer’s commitment to being a pure-play pharmaceutical company. In long-term strategy discussions, such discipline strengthens its profile as a stronger, more focused contender in the pharmaceutical sector.
Competitive Landscape: Pfizer vs Rivals
Pfizer operates in a fiercely competitive environment. Moderna continues to push forward with mRNA innovations, Johnson & Johnson remains strong in diversified healthcare, and Novo Nordisk dominates the obesity treatment market.
Where Pfizer differentiates itself is scale and pipeline diversity. Its oncology portfolio is expanding, rare disease assets are gaining traction, and its vaccine platform remains world-class. Unlike smaller biotechs, Pfizer has the financial resources to weather product setbacks and reinvest aggressively.
Competitive Comparison
| Company | Strengths | Weaknesses |
| Pfizer (PFE) | Diversified portfolio, strong dividend, global reach | Obesity drug setback, slower growth |
| Moderna (MRNA) | Innovative mRNA platform, rapid R&D | Heavy reliance on COVID-19 products |
| Johnson & Johnson (JNJ) | Diversified healthcare model, strong balance sheet | Legal risks in consumer health |
| Novo Nordisk (NVO) | Market leader in obesity/diabetes drugs | Limited diversification beyond metabolic diseases |
Traders analyzing Fintechzoom PFE stock often compare it against peers when considering healthcare allocations. While competitors may deliver faster growth, Pfizer’s mix of dividends, pipeline optionality, and size often earns it a spot among conservative lists of Fintechzoom best stocks to buy now.
When is Pfizer’s Next Earnings Report?
Pfizer’s next earnings report is expected later this fall (Q3 2025). Investors are particularly interested in updates on oncology sales, COVID-19 vaccine uptake for the winter season, and progress on pipeline programs outside obesity.
For short-term traders, earnings releases often drive volatility in Fintechzoom PFE stock. For long-term investors, each quarter provides clarity on whether Pfizer is delivering consistent revenue streams and meeting cost-cutting targets.
Dividend Yield and Payout History
One of Pfizer’s strongest attractions is its dividend history. Currently, the company offers an above-market dividend yield, making it appealing to income-focused portfolios.
Pfizer has a reputation for maintaining shareholder returns even during challenging business cycles. The stability of its dividend has led many conservative investors to favor it over higher-growth but riskier biotech names.
Because of this track record, many analysts highlight Pfizer as a reliable option for investors who prioritize income and long-term stability.
Analyst Sentiment: Buy, Sell, or Hold?
Wall Street analysts remain divided on Pfizer. Some view it as undervalued at current levels, pointing to the raised 2025 profit forecast and pipeline potential. Others worry about missed opportunities in obesity treatments and slower growth in post-pandemic vaccines.
Consensus is currently around a “Hold”, with select analysts recommending “Buy” given the attractive dividend and low valuation.
The mixed outlook reflects both opportunity and caution. Many conservative investors still view Pfizer as a defensive healthcare play, making it a steady choice for long-term portfolios.
Conclusion
Pfizer remains one of the most watched pharmaceutical stocks in the world. With a stock price hovering around the mid-$20s, consistent dividends, and a sharpened focus on innovation, it continues to attract attention from value and income investors alike.
The company’s decision to halt its obesity drug is a setback, but strong vaccine performance, oncology progress, and disciplined financial management provide a stable foundation. Its exit from Haleon underscores Pfizer’s commitment to focusing purely on pharmaceuticals, while cost-cutting measures signal efficiency gains for the future.
Whether Pfizer belongs on every investor’s watchlist depends on strategy. For those seeking high-risk, high-growth plays, smaller biotechs may offer more upside. But for investors valuing stability, dividends, and global healthcare exposure, Fintechzoom PFE stock remains a contender in conversations about the Fintechzoom best stocks to buy now.
FAQs
Q: What are Pfizer’s major upcoming drug launches?
A: Pfizer has several pipeline products expected to reach late-stage clinical trials or regulatory approval in the next 12–18 months, including new oncology treatments, immunology biologics, and next-generation vaccines for influenza and RSV.
Q: How does Pfizer approach mergers and acquisitions?
A: Pfizer has historically acquired smaller biotech firms to strengthen its pipeline. The company focuses on strategic acquisitions that complement its core therapeutic areas, particularly oncology, rare diseases, and vaccines.
Q: What is Pfizer’s strategy for emerging markets?
A: Pfizer is expanding its presence in Asia, Latin America, and Africa, focusing on both vaccines and high-demand prescription drugs. Partnerships with local governments and global health organizations help drive growth in these regions.
Q: How does Pfizer invest in research and development (R&D)?
A: Pfizer spends billions annually on R&D, often targeting breakthrough therapies in oncology, immunology, and rare diseases. The company emphasizes innovation through collaborations with biotech firms and academic institutions.
Q: What are the key risks facing Pfizer’s stock?
A: Risks include regulatory hurdles, patent expirations on major drugs, competitive pressures from other pharmaceutical companies, and potential setbacks in clinical trials. Currency fluctuations and changes in healthcare policy also affect financial performance.
Q: How does Pfizer handle environmental, social, and governance (ESG) responsibilities?
A: Pfizer emphasizes sustainable operations, ethical supply chains, and access to medicines globally. The company publishes annual ESG reports detailing initiatives in carbon reduction, diversity, and community health programs.
Q: Can retail investors buy Pfizer stock directly through dividend reinvestment plans (DRIPs)?
A: Yes, Pfizer offers programs for shareholders to reinvest dividends automatically, allowing long-term investors to compound returns over time without incurring additional brokerage fees.
